tbuckley/cabot-search huggingface dataset:
Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy
Authors: Jin-Qing Liu, Chengxiang Zhang, Xinfu Zhang, Jingyue Yan, Chunxi Zeng, Fatemeh Talebian, Kimberly Lynch, Weiyu Zhao, Xucheng Hou, Shi Du, Diana D. Kang, Binbin Deng, David W. McComb, Xue-Feng Bai, Yizhou Dong
Journal: Journal of Controlled Release (2022)
Response to ‘Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin’: reply from the authors
Authors: Caitlin L. Penny, Krystina Quow, Chandler W. Rundle, Rami N. Al‐Rohil, Adela R. Cardones, Meenal K. Kheterpal, Amber I. Fresco
Journal: British Journal of Dermatology (2022)

-
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial
Authors: Carlo Salvarani, Marco Massari, Massimo Costantini, Domenico Franco Merlo, Gabriella Lucia Mariani, Pierluigi Viale, Stefano Nava, Giovanni Guaraldi, Giovanni Dolci, Luca Boni, Luisa Savoldi, Paolo Bruzzi, Caterina Turrà, Mariagrazia Catanoso, Anna Maria Marata, Chiara Barbieri, Annamaria Valcavi, Francesca Franzoni, Silvio Cavuto, Giorgio Mazzi, Romina Corsini, Fabio Trapani, Alessandro Bartoloni, Emanuela Barisione, Chiara Barbieri, Giulia Jole Burastero, Angelo Pan, Walter Inojosa, Raffaele Scala, Cecilia Burattini, Fabrizio Luppi, Mauro Codeluppi, Kamal Eldin Tarek, Giovanni Cenderello, Mario Salio, Giuseppe Foti, Roberto Dongilli, Gianluigi Bajocchi, Emanuele Alberto Negri, Giacomo Ciusa, Giacomo Fornaro, Ilaria Bassi, Lorenzo Zammarchi, Teresita Aloè, Nicola Facciolongo
Journal: European Respiratory Journal (2022)

Rationale Pulse glucocorticoid therapy is used in hyperinflammation related to coronavirus disease 2019 (COVID-19). We evaluated the efficacy and safety of pulse intravenous methylprednisolone in addition to standard treatment in COVID-19 pneumonia. Methods In this multicentre, randomised, double-blind, placebo-controlled trial, 304 hospitalised patients with COVID-19 pneumonia were randomised to receive 1 g of methylprednisolone intravenously for three consecutive days or placebo in addition to standard dexamethasone. The primary outcome was the duration of patient hospitalisation, calculated as the time interval between randomisation and hospital discharge without the need for supplementary oxygen. The key secondary outcomes were survival free from invasive ventilation with orotracheal intubation and overall survival. Results Overall, 112 (75.4%) out of 151 patients in the pulse methylprednisolone arm and 111 (75.2%) of 150 in the placebo arm were discharged from hospital without oxygen within 30 days from randomisation. Median time to discharge was similar in both groups (15 days, 95% CI 13.0–17.0 days and 16 days, 95% CI 13.8–18.2 days, respectively; hazard ratio (HR) 0.92, 95% CI 0.71–1.20; p=0.528). No significant differences between pulse methylprednisolone and placebo arms were observed in terms of admission to intensive care unit with orotracheal intubation or death (20.0% versus 16.1%; HR 1.26, 95% CI 0.74–2.16; p=0.176) or overall mortality (10.0% versus 12.2%; HR 0.83, 95% CI 0.42–1.64; p=0.584). Serious adverse events occurred with similar frequency in the two groups. Conclusions Methylprenisolone pulse therapy added to dexamethasone was not of benefit in patients with COVID-19 pneumonia.
Iron out KRAS-driven cancer
Authors: Guang Lei, Boyi Gan
Journal: The Journal of Experimental Medicine (2022)

How to specifically target oncogenic KRAS-driven cancers while sparing normal tissues remains an unmet need in cancer therapy. In this issue of JEM, Jiang et al. (2022. J. Exp. Med.https://doi.org/10.1084/jem.20210739) leveraged KRAS-induced iron addiction in cancer cells to design a clever drug delivery approach to enable selective inhibition of KRAS signaling in mutant KRAS tumors but not in normal tissues, offering a new strategy for treating this largely incurable disease.
Target-oriented prioritization: targeted selection strategy by integrating organismal and molecular traits through predictive analytics in breeding
Authors: Wenyu Yang, Tingting Guo, Jingyun Luo, Ruyang Zhang, Jiuran Zhao, Marilyn L. Warburton, Yingjie Xiao, Jianbing Yan
Journal: Genome biology (2022)

Genomic prediction in crop breeding is hindered by modeling on limited phenotypic traits. We propose an integrative multi-trait breeding strategy via machine learning algorithm, target-oriented prioritization (TOP). Using a large hybrid maize population, we demonstrate that the accuracy for identifying a candidate that is phenotypically closest to an ideotype, or target variety, achieves up to 91%. The strength of TOP is enhanced when omics level traits are included. We show that TOP enables selection of inbreds or hybrids that outperform existing commercial varieties. It improves multiple traits and accurately identifies improved candidates for new varieties, which will greatly influence breeding.
Intra-articular Platelet-Rich Plasma vs Placebo Injection and Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis
Authors: Zhaohua Zhu, Changhai Ding
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Distinct bronchial microbiome precedes clinical diagnosis of lung cancer
Authors: Erin A. Marshall, Fernando S. L. Filho, Don D. Sin, Stephen Lam, Janice M. Leung, Wan L. Lam
Journal: Molecular Cancer (2022)

Abstract Resident microbial populations have been detected across solid tumors of diverse origins. Sequencing of the airway microbiota represents an opportunity for establishing a novel omics approach to early detection of lung cancer, as well as risk prediction of cancer development. We hypothesize that bacterial shifts in the pre-malignant lung may be detected in non-cancerous airway liquid biopsies collected during bronchoscopy. We analyzed the airway microbiome profile of near 400 patients: epithelial brushing samples from those with lung cancer, those who developed an incident cancer, and those who do not develop cancer after 10-year follow-up. Using linear discriminate analysis, we define and validate a microbial-based classifier that is able to predict incident cancer in patients before diagnosis with no clinical signs of cancer. Our results demonstrate the potential of using lung microbiome profiling as a method for early detection of lung cancer.
Redox signaling at the crossroads of human health and disease
Authors: Jing Zuo, Zhe Zhang, Maochao Luo, Li Zhou, Edouard C. Nice, Wei Zhang, Chuang Wang, Canhua Huang
Journal: MedComm (2022)

Abstract Redox biology is at the core of life sciences, accompanied by the close correlation of redox processes with biological activities. Redox homeostasis is a prerequisite for human health, in which the physiological levels of nonradical reactive oxygen species (ROS) function as the primary second messengers to modulate physiological redox signaling by orchestrating multiple redox sensors. However, excessive ROS accumulation, termed oxidative stress (OS), leads to biomolecule damage and subsequent occurrence of various diseases such as type 2 diabetes, atherosclerosis, and cancer. Herein, starting with the evolution of redox biology, we reveal the roles of ROS as multifaceted physiological modulators to mediate redox signaling and sustain redox homeostasis. In addition, we also emphasize the detailed OS mechanisms involved in the initiation and development of several important diseases. ROS as a double‐edged sword in disease progression suggest two different therapeutic strategies to treat redox‐relevant diseases, in which targeting ROS sources and redox‐related effectors to manipulate redox homeostasis will largely promote precision medicine. Therefore, a comprehensive understanding of the redox signaling networks under physiological and pathological conditions will facilitate the development of redox medicine and benefit patients with redox‐relevant diseases.
CLO22-083: Impact of Body Mass Index (BMI) on the Unplanned Need for Whole Breast Radiation Therapy (WBRT) Following Intra-Operative Electronic Brachyterapy for Early-Stage Breast Cancer
Authors: Barbara S Schwartzberg, A. M. Nisar Syed, Craig Wengler
Journal: Journal of the National Comprehensive Cancer Network (2022)

"CLO22-083: Impact of Body Mass Index (BMI) on the Unplanned Need for Whole Breast Radiation Therapy (WBRT) Following Intra-Operative Electronic Brachyterapy for Early-Stage Breast Cancer" published on 31 Mar 2022 by National Comprehensive Cancer Network.
Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer
Authors: Hui Zhou, Liyong Zhu, Jun Song, Guohui Wang, Pengzhou Li, Weizheng Li, Ping Luo, Xulong Sun, Jin Wu, Yunze Liu, Shaihong Zhu, Yi Zhang
Journal: Molecular Cancer (2022)

Abstract Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading cause of carcinogenic death. To date, surgical resection is regarded as the gold standard by the operator for clinical decisions. Because conventional tissue biopsy is invasive and only a small sample can sometimes be obtained, it is unable to represent the heterogeneity of tumor or dynamically monitor tumor progression. Therefore, there is an urgent need to find a new minimally invasive or noninvasive diagnostic strategy to detect CRC at an early stage and monitor CRC recurrence. Over the past years, a new diagnostic concept called “liquid biopsy” has gained much attention. Liquid biopsy is noninvasive, allowing repeated analysis and real-time monitoring of tumor recurrence, metastasis or therapeutic responses. With the advanced development of new molecular techniques in CRC, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and tumor-educated platelet (TEP) detection have achieved interesting and inspiring results as the most prominent liquid biopsy markers. In this review, we focused on some clinical applications of CTCs, ctDNA, exosomes and TEPs and discuss promising future applications to solve unmet clinical needs in CRC patients.
Research priorities to improve stroke outcomes
Authors: Georgina Hill, Sandra Regan, Richard Francis, Gillian Mead, Shirley Thomas, Rustam Al-Shahi Salman, Christine Roffe, Alex Pollock, Sally Davenport, Eirini Kontou, Katie Chadd, Ulrike Hammerbeck, Adewale O Adebajo, Catherine Elizabeth Lightbody, Jenny Crow, Niamh Kennedy, Nicholas Evans, Thompson G. Robinson
Journal: The Lancet Neurology (2022)
LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer
Authors: Dan-Dan Shen, Jing-Ru Pang, Ya-Ping Bi, Long-Fei Zhao, Yin-Rui Li, Li-Juan Zhao, Ya Gao, Bo Wang, Ning Wang, Liuya Wei, Huiqin Guo, Hong-Min Liu, Yi-Chao Zheng
Journal: Molecular Cancer (2022)

Histone lysine-specific demethylase 1 (LSD1) expression has been shown to be significantly elevated in gastric cancer (GC) and may be associated with the proliferation and metastasis of GC. It has been reported that LSD1 repressed tumor immunity through programmed cell death 1 ligand 1 (PD-L1) in melanoma and breast cancer. The role of LSD1 in the immune microenvironment of GC is unknown.Expression LSD1 and PD-L1 in GC patients was analyzed by immunohistochemical (IHC) and Western blotting. Exosomes were isolated from the culture medium of GC cells using an ultracentrifugation method and characterized by transmission electronic microscopy (TEM), nanoparticle tracking analysis (NTA), sucrose gradient centrifugation, and Western blotting. The role of exosomal PD-L1 in T-cell dysfunction was assessed by flow cytometry, T-cell killing and enzyme-linked immunosorbent assay (ELISA).Through in vivo exploration, mouse forestomach carcinoma (MFC) cells with LSD1 knockout (KO) showed significantly slow growth in 615 mice than T-cell-deficient BALB/c nude mice. Meanwhile, in GC specimens, expression of LSD1 was negatively correlated with that of CD8 and positively correlated with that of PD-L1. Further study showed that LSD1 inhibited the response of T cells in the microenvironment of GC by inducing the accumulation of PD-L1 in exosomes, while the membrane PD-L1 stayed constant in GC cells. Using exosomes as vehicles, LSD1 also obstructed T-cell response of other cancer cells while LSD1 deletion rescued T-cell function. It was found that while relying on the existence of LSD1 in donor cells, exosomes can regulate MFC cells proliferation with distinct roles depending on exosomal PD-L1-mediated T-cell immunity in vivo.LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in GC; this finding indicates a new mechanism with which LSD1 may regulate cancer immunity in GC and provides a new target for immunotherapy against GC.
Prospective Study Assessing Impact of Ethylene Oxide Sterilization on Endoscopic Ultrasound Image Quality
Authors: Shounak Majumder, Zaiyang Long, Alexander W Hooke, Bret T Petersen, Ferga C Gleeson, Marco Bruno, John DeWitt, Grace Elta, Larissa Fuji, Victoria Gomez, Laurent Palazzo, Vanessa M Shami, Tyler Stevens, Mark D Topazian, Maurits J Wiersema, Lawrence J Berglund, Barham K Abu Dayyeh, Vinay Chandrasekhara, Prasad G Iyer, Elizabeth Rajan, Andrew C Storm, Kenneth K Wang, Ryan Lennon, Joseph J Larson, Felicity T Enders, Jed R Frein, Raymond A Yates, Nicholas J Hangiandreou, Michael J Levy
Journal: Clinical Gastroenterology and Hepatology (2022)
PERCUTANEOUS ECMO-ASSOCIATED HARLEQUIN (NORTH-SOUTH) SYNDROME FOLLOWING V-A ECMO INITIATION
Authors: Abhinav Karan, Okechukwu Mgbemena, Fabiana Rollini, Bashar Al-Turk, Kevin Liu, Jose Rivas, Pooja Dhruva, Alexa Peterson, Jean-Christophe Rwigema, Kevin Durgin, Michael Gill, Joseph Shiber, Matthew Kochuba, Firas Madbak, Brian Yorkgitis, David Skarupa
Journal: Journal of the American College of Cardiology (2022)
Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
Authors: Abdul Hamid Bazarbachi, Rama Al Hamed, Florent Malard, Ali Bazarbachi, Jean-Luc Harousseau, Mohamad Mohty
Journal: Blood Cancer Journal (2022)

Abstract The current standard of care model for newly diagnosed fit multiple myeloma (NDMM) patients is the sequential treatment of induction, high dose melphalan, autologous stem cell transplantation (ASCT), and maintenance. Adequate induction is required to achieve good disease control and induce deep response rates while minimizing toxicity as a bridge to transplant. Doublet induction regimens have greatly fallen out of favor, with current international guidelines favoring triplet or quadruplet induction regimens built around the backbone of the proteasome inhibitor bortezomib and dexamethasone (Vd). In fact, the updated 2021 European Haematology Association (EHA) and European Society for Medical Oncology (ESMO) clinical practice guidelines recommend the use of either lenalidomide-Vd (VRd), or daratumumab-thalidomide-Vd (Dara-VTd) as first-line options for transplant-eligible NDMM patients, and when not available, thalidomide-Vd (VTd) or cyclophosphamide-Vd (VCd) as acceptable alternatives. Quadruplet regimens featuring anti-CD38 monoclonal antibodies are extremely promising and remain heavily investigated, as is the incorporation of more recent proteasome inhibitors such as carfilzomib. This review will focus on induction therapies prior to ASCT examining the latest data and guidelines on triplet and quadruplet regimens.
SCALABLE DIGITAL SOLUTIONS TO ADDRESS PATIENT-CENTERED AMBULATORY CARDIOVASCULAR CARE IN THE GREATER ROCHESTER REGION
Authors: Jessica W. Oribabor, Frederick Ling, Leway Chen, Ilan Goldenberg, Chris DaSilva, Allison McIntyre, Judith Baumhauer, Charles J. Lowenstein, Jeffrey Bruckel
Journal: Journal of the American College of Cardiology (2022)
Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies
Authors: Denise Haslwanter, Gorka Lasso, Anna Z. Wec, Nathália Dias Furtado, Lidiane Menezes Souza Raphael, Alexandra L. Tse, Yan Sun, Stephanie Stransky, Núria Pedreño-Lopez, Carolina Argondizo Correia, Zachary A. Bornholdt, Mrunal Sakharkar, Vivian I. Avelino-Silva, Crystal L. Moyer, David I. Watkins, Esper G. Kallas, Simone Sidoli, Laura M. Walker, Myrna C. Bonaldo, Kartik Chandran
Journal: Cell Host & Microbe (2022)
Hemiplegia
Authors: Jane Newkirk
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Drug delivery for metabolism targeted cancer immunotherapy
Authors: Taravat Khodaei, Sahil Inamdar, Abhirami P. Suresh, Abhinav P. Acharya
Journal: Advanced Drug Delivery Reviews (2022)

Drug delivery vehicles have made a great impact on cancer immunotherapies in clinics and pre-clinical research. Notably, the science of delivery of cancer vaccines and immunotherapeutics, modulating immune cell functions has inspired development of several successful companies and clinical products. Interestingly, these drug delivery modalities not only modulate the function of immune cells (often quantified at the mRNA and protein levels), but also modulate the metabolism of these cells. Specifically, cancer immunotherapy often leads to activation of different immune cells such as dendritic cells, macrophages and T cells, which is driven by energy metabolism of these cells. Recently, there has been a great excitement about interventions that can directly modulate the energy metabolism of these immune cells and thus affect their function and in turn lead to a robust cancer immune response. Here we review few strategies that have been tested in clinic and pre-clinical research for generating effective metabolism-associated cancer therapies and immunotherapies.
Early Outpatient Treatment for Covid-19 with Convalescent Plasma
Authors: David J. Sullivan, Kelly A. Gebo, Shmuel Shoham, Evan M. Bloch, Bryan Lau, Aarthi G. Shenoy, Giselle S. Mosnaim, Thomas J. Gniadek, Yuriko Fukuta, Bela Patel, Sonya L. Heath, Adam C. Levine, Barry R. Meisenberg, Emily S. Spivak, Shweta Anjan, Moises A. Huaman, Janis E. Blair, Judith S. Currier, James H. Paxton, Jonathan M. Gerber, Joann R. Petrini, Patrick B. Broderick, William Rausch, Marie-Elena Cordisco, Jean Hammel, Benjamin Greenblatt, Valerie C. Cluzet, Daniel Cruser, Kevin Oei, Matthew Abinante, Laura L. Hammitt, Catherine G. Sutcliffe, Donald N. Forthal, Martin S. Zand, Edward R. Cachay, Jay S. Raval, Seble G. Kassaye, E. Colin Foster, Michael Roth, Christi E. Marshall, Anusha Yarava, Karen Lane, Nichol A. McBee, Amy L. Gawad, Nicky Karlen, Atika Singh, Daniel E. Ford, Douglas A. Jabs, Lawrence J. Appel, David M. Shade, Stephan Ehrhardt, Sheriza N. Baksh, Oliver Laeyendecker, Andrew Pekosz, Sabra L. Klein, Arturo Casadevall, Aaron A.R. Tobian, Daniel F. Hanley
Journal: New England Journal of Medicine (2022)

Polyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing serious complications in outpatients with recent-onset Covid-19 is uncertain.